HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review.

AbstractBACKGROUND:
Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known.
METHODS:
We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012.
RESULTS:
We reviewed the records of 87 patients with inoperable colorectal cancer who received SEMS during our study period. Nine perforations occurred in total: 4 of 30 (13%) patients who received no chemotherapy, 3 of 47 (6%) who received chemotherapy but no bevacizumab, and 2 of 10 (20%) who received chemotherapy and bevacizumab. These two patients received bevacizumab with FOLFIRI after SEMS placement, and they had peritoneal disease.
CONCLUSION:
Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.
AuthorsAmal Imbulgoda, Anthony MacLean, John Heine, Sebastien Drolet, Michael M Vickers
JournalCanadian journal of surgery. Journal canadien de chirurgie (Can J Surg) Vol. 58 Issue 3 Pg. 167-71 (Jun 2015) ISSN: 1488-2310 [Electronic] Canada
PMID25799132 (Publication Type: Evaluation Study, Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Adenocarcinoma (complications, drug therapy)
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Bevacizumab
  • Colonic Diseases (etiology, therapy)
  • Colorectal Neoplasms (complications, drug therapy)
  • Combined Modality Therapy
  • Female
  • Humans
  • Intestinal Obstruction (etiology, therapy)
  • Intestinal Perforation (etiology)
  • Male
  • Middle Aged
  • Palliative Care (methods)
  • Retrospective Studies
  • Stents (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: